Comparison of long-term outcomes of 50 and 100mg rt-PA in the management of acute pulmonary thromboembolism

YILMAZEL UÇAR E., ARAZ Ö., KERGET B., YILMAZ N., AKGÜN M., SAĞLAM L.

CLINICAL RESPIRATORY JOURNAL, cilt.12, sa.4, ss.1628-1634, 2018 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/crj.12721
  • Dergi Adı: CLINICAL RESPIRATORY JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1628-1634
  • Anahtar Kelimeler: long-term outcomes, pulmonary thromboembolism, thrombolytic therapy, DEEP-VEIN THROMBOSIS, PLASMINOGEN-ACTIVATOR, THROMBOLYTIC THERAPY, ANTITHROMBOTIC THERAPY, EUROPEAN-SOCIETY, TASK-FORCE, EMBOLISM, DIAGNOSIS, RISK, HYPERTENSION
  • Atatürk Üniversitesi Adresli: Evet

Özet

BackgroundPulmonary thromboembolism (PTE) is a life-threatening disease. In this study, we aimed to evaluate long-term outcomes of the use of 50mg recombinant tissue-type plasminogen activator (rt-PA) in the management of PTE in terms of relapse, pulmonary hypertension (PH), mortality and hemorrhage and to compare with the use of 100mg rt-PA.